In This Article:
-
All proposals of the Board of Directors approved.
-
Dividend of CHF 0.85 per share.
Bubendorf, Switzerland--(Newsfile Corp. - April 30, 2025) - Bachem Holding AG (SIX: BANB) (“Bachem”) announced today that its Annual General Meeting 2025 has approved all proposals of the Board of Directors. A total of 79.7% of the 74‘977‘940 eligible shares were present.
The Annual General Meeting approved a dividend of CHF 0.85 per share. The dividend will be paid on May 7, 2025. The last trading day entitling to receive the dividend is May 2, 2025. As of May 5, 2025, the shares will be traded ex-dividend.
Both the Chairman and the other members of the Board of Directors were re-elected for a further year. Dr. Simone Wyss Fedele was elected as a new member of the Board. The existing members of the Compensation Committee were also re-elected for a further year.
The shareholders approved the annual report, the financial statements of Bachem Holding AG, the consolidated financial statements for the business year 2024, as well as the appropriation of retained earnings and reserves from capital contributions and the total amount of the annual compensation paid to the Board of Directors and to the Corporate Executive Committee. Further, the shareholders approved the sustainability report and, in a consultative vote, the remuneration report.
Forvis Mazars SA, Zurich was appointed by the Annual General Meeting as auditor of Bachem Holding AG for the business year 2025.
A detailed list of all resolutions will be made available at
https://www.bachem.com/about-bachem/investors-and-media/financial-events/.
Financial Calendar
May 7, 2025 Payout date for dividend
July 24, 2025 Publication of Half-Year Report 2025
March 12, 2026 Publication of Annual Report 2025; Media and Analyst conference
April 29, 2026 Annual General Meeting (financial year 2025)
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.